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OBJECTIVES This study was designed to study the influence of diabetes on the outcome of unstable
coronary artery disease (CAD).
BACKGROUND Diabetes mellitus is a major contributor to CAD. Despite improvement in the management
of patients with unstable coronary syndromes, this condition is still linked to a substantially
increased mortality and morbidity among diabetic patients. Recent evidence advocates early
revascularization in unstable coronary syndromes. Diabetic patients subjected to coronary
interventions under stable conditions have a higher risk for complications and a more dismal
prognosis than nondiabetic subjects. Accordingly, it is of considerable interest to obtain
further information regarding the best possible management of diabetic patients with unstable
CAD.
METHODS A total of 2,158 patients without and 299 with diabetes mellitus were randomized to an early
invasive or a noninvasive strategy. The severity of CAD was expressed as the number and
extent of vessel involvement.
RESULTS Three-vessel disease was diagnosed in 42% of diabetic and 31% of nondiabetic patients (p 
0.006). The percentages of patients with ST-depression and troponin-T 0.03 g/l at
admission were comparable among diabetic and nondiabetic patients. Mortality and rein-
farction after 12 months were more frequent among diabetic than nondiabetic patients in
both treatment groups. Diabetes remained a strong independent predictor for death and
myocardial infarction in multivariable analysis. The invasive strategy reduced event rate in
nondiabetic patients from 12.0% to 8.9% (odds ratio [OR]  0.72; confidence interval [CI]
0.54 to 0.95; p  0.019) and in diabetic patients from 29.9% to 20.6% (OR 0.61; CI 0.36 to
1.04; p  0.066). In a multivariate analysis including the extent of CAD, diabetes remained
a strong independent predictor of the combined end point (relative risk [RR] 2.40; CI 1.47
to 3.91; p  0.0001) and of mortality (RR 5.43; CI 2.09 to 14.12; p  0.001).
CONCLUSIONS An invasive strategy improved outcome for both diabetic and nondiabetic patients with
unstable CAD. However, diabetes mellitus remained an independent and important risk
factor for death and myocardial infarction in the invasive group. Thus, factors beyond the
extent of flow-limiting coronary lesions are of considerable importance for outcome in
diabetic subjects with unstable coronary syndromes. (J Am Coll Cardiol 2004;43:585–91)
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omong risk factors for coronary artery disease (CAD),
iabetes mellitus (DM) is a major contributor, not only to
he development of CAD but also to outcome following
arious manifestations of the disease. In fact, increasing
evels of blood glucose, even below the level of established
iabetes, serve as predictors of increased risk (1). Despite
mprovement in the management of patients with unstable
oronary syndromes, unstable CAD is still linked to a
ubstantially increased mortality and morbidity among dia-
etic patients, as demonstrated by the OASIS and GUSTO
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nd †Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden. The
RISC II trial was supported by and organized in collaboration with the Pharmacia
nd Upjohn Company. The Swedish Heart-Lung Foundation supported this part of
he study.
Manuscript received June 12, 2003; revised manuscript received August 15, 2003,
pccepted August 26, 2003.I trials (2,3). Because the prevalence of DM in patients
ith myocardial infarction (MI) is high, and the prevalence
n the general population is expected to increase in coming
ecades (4), management of the diabetic patient cohort will
ubstantially affect total morbidity and mortality in this
isease.
Recent evidence advocates early revascularization in un-
table coronary syndromes (5,6). Diabetic patients subjected
o coronary interventions under stable conditions have a
igher risk for complications and a more dismal prognosis
han nondiabetic subjects (7–9). Diabetic patients more
ften have three-vessel disease and a more diffuse coronary
rtery involvement than their nondiabetic counterparts
10,11), factors that may contribute to the less favorable
utcome following revascularization. Accordingly, it is im-
ortant to determine whether the best management of
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Diabetes: Major Risk in Unstable Angina February 18, 2004:585–91iabetic patients with unstable CAD involves immediate
evascularization or a more conservative approach based on
harmacologic therapy.
The FRISC II database offers unique opportunities to
xplore the best possible treatment of diabetic patients with
nstable CAD. The present study describes the association
etween diabetes and outcome in relation to the extent of
AD and other risk factors of prognostic importance and
nvestigates whether early revascularization improves the
rognosis for patients with diabetes.
ATERIALS AND METHODS
he FRISC II invasive study was a prospective, randomized
ulticenter trial recruiting patients admitted to hospital
ecause of unstable CAD. Full details on this study have
een given elsewhere (12,13). Eligible patients were ran-
omized as soon as possible, but at the latest within 72 h
fter the start of open-label dalteparin (or standard heparin),
o one of four treatment policies: invasive strategy and
ong-term dalteparin, invasive strategy and long-term pla-
ebo, noninvasive strategy and long-term dalteparin, or
oninvasive strategy and long-term placebo. With the
nvasive strategy, the target was to perform all invasive
rocedures within seven days after starting open-label dalte-
arin. The comparison of the invasive and noninvasive
trategies was not blinded. Follow-up lasted 12 months.
atients. Patients were eligible for inclusion if they had
ymptoms of ischemia that were increasing or occurring at
est or warranting the suspicion of acute MI, with the last
pisode preceding the first dose of dalteparin or standard
eparin by48 h. Furthermore, myocardial ischemia had to
e verified by electrocardiogram (ECG) (ST-depression
0.1 mV or T-wave inversion0.1 mV), or by elevation of
iochemical markers (creatine kinase [CK]-MB 6 g/l,
roponin-T 0.10 g/l, qualitative troponin-T test posi-
ive, or catalytic activity of CK, CK-B, or CK-MB above
he local decision limit for the diagnosis of MI). The
xclusion criteria included raised risk of bleeding or anemia,
ndication for or treatment with thrombolysis within the
ast 24 h, angioplasty performed within the past six months,
n a waiting list for coronary revascularization procedure,
ther acute or severe cardiac disease, renal insufficiency
Abbreviations and Acronyms
CABG  coronary artery bypass graft
CAD  coronary artery disease
CK  creatine kinase
DM  diabetes mellitus
ECG  electrocardiogram
MI  myocardial infarction
PCI  percutaneous coronary intervention
RIKS-HIA  Register of Information and Knowledge
about Swedish Heart Intensive
RR  risk ratiocreatinine 150 mol/l), hepatic insufficiency, known alinically relevant osteoporosis, other severe illness, hyper-
ensitivity to randomized drugs, anticipated problems of
ooperation, or participation in this or another clinical trial.
atients with previous open-heart surgery, advanced age
above 75 years), or other conditions that, in the investiga-
or’s judgment, made randomization to revascularization
nappropriate were not eligible. The criteria for diabetes in
his study were that the diagnosis was known to the patient
nd that treatment had been prescribed with diet, oral
ntidiabetic drugs, or insulin.
ntervention strategies. The direct invasive strategy re-
uired coronary angiography within a few days of enroll-
ent, aiming for revascularization within seven days from
he start of open-label dalteparin (or standard heparin).
evascularization was recommended in all patients with a
70% diameter obstruction in any artery supplying a
ignificant proportion of the myocardium. Percutaneous
oronary intervention (PCI) was recommended if there were
ne or two target lesions, whereas coronary artery bypass
rafting (CABG) was to be preferred in patients with
hree-vessel or left main disease.
The noninvasive strategy included coronary angiography
n patients with refractory or recurrent symptoms (despite
aximal medical treatment) or severe ischemia at a predis-
harge symptom-limited exercise test (12). During follow-
p, invasive procedures were to be considered, regardless of
andomized strategy, for all patients with incapacitating
ymptoms, recurrence of instability, or MI.
pen and double-blind dalteparin treatment. On admis-
ion, the patients were initially treated with either subcuta-
eous dalteparin or APTT-adjusted standard heparin infu-
ion. From randomization, all patients received dalteparin,
20 IU/kg/12 h subcutaneously (maximal dose 10,000 IU),
or at least five days, and always until invasive procedures.
hereafter, the patients received twice-daily subcutaneous
njections of either dalteparin or placebo for three months
12).
oncomitant therapies. Aspirin was administered to all
atients on admission in an initial dose of 300 to 600 mg
ollowed by a maintenance dose of 75 to 320 mg once daily.
eta-blockers was given unless contraindicated. Organic
itrates and calcium antagonists could be added as required.
holesterol lowering with statins, angiotensin-converting
nzyme inhibitors for left ventricular dysfunction, and
ggressive antidiabetic treatment were recommended, ac-
ording to modern European treatment guidelines. The use
f the glycoprotein IIb/IIIa receptor inhibitor abciximab
uring PCI was encouraged. Ticlopidine was recommended
or three to four weeks after stent placement. All ECGs and
xercise tests were sent to a core laboratory for evaluation.
xtent of CAD. Based on the coronary arteriographic
ndings, the extent of CAD was expressed in two ways. The
rst was a simple classification in one-, two-, and three-
including left main) vessel disease. In the second a coronary
atheroma score” was constructed by dividing the coronary
rteries from each patient, depending on differences in
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February 18, 2004:585–91 Diabetes: Major Risk in Unstable Anginanatomy, into a maximum of 15 segments (14). Each
egment was visually analyzed for atheromatosis and the
xtent of stenosis and given a score based on the maximum
egree of narrowing (0 for no stenosis, 1 for stenosis 50%,
for 50% to 70% obstruction, 3 for 70% to 100%, and
for total occlusion). An “atheroma score” (0 to 1) was
ubsequently derived for each patient as the sum of observed
cores divided by the theoretical maximum score (corre-
ponding to total occlusion in all evaluable segments).
fficacy end points. The primary end point was a com-
osite end point of death or MI. Myocardial infarction was
ased on the presence of two out of the conventional three
riteria: typical chest pain, diagnostic ECG recording
mainly new Q-wave), or elevation of biochemical markers
f myocardial damage. The decision levels for biochemical
arkers of myocardial damage in relation to nonprocedural
nd procedure-related MI have previously been detailed
13). Only new Q-waves were used for the diagnosis of MI
n association with CABG. Autopsy was recommended to
stablish cause of death. During the first six months, all
eported deaths, MIs, elevation of biochemical markers in
elation to PCI procedures, and new Q-waves reported by
he ECG core laboratory were adjudicated by an indepen-
ent clinical event committee. After this period, informa-
ion on further events was evaluated by the local investigator
n the basis of outpatient visits or telephone contacts with
ll surviving patients and, in the case of readmission to
ospital, on hospital records. The cause of death during this
eriod was based either on hospital records or on death
ertificates.
tatistics and data management. All statistical analyses
ere performed on an intention-to-treat basis. The efficacy
nalyses were based on events occurring from the start of
pen-label dalteparin treatment until 12 months. Analyses
ere also performed in predefined subgroups. The efficacy
nalyses of the one-year follow-up were point estimates
ncluding only patients with an adjudicated event or with
ecorded absence of the evaluated event until at least day
65 of follow up. Student’s t test or Pearson chi-squared test
as used to test the significance between patients with and
ithout DM. The Mantel-Haenszel chi-square test was
sed to determine the significance of the overall degree of
ssociation. The results are presented as the risk ratio with
5% confidence interval. No adjustment was made for
ultiple comparisons. Graphs of the Kaplan-Meier esti-
ate of the survival function were used without statistical
nalysis. The occurrence of possible interactions between
he randomized invasive strategy and other factors was
valuated by logistic multiple regression analysis. The coor-
inating investigators, using the SPSS 10.1 statistical pro-
ram for personal computer, performed the data processing
nd statistical analyses. The study complied with the Dec-
aration of Helsinki, and all local ethics committees ap-
roved the protocol.ESULTS
total of 2,457 patients, 299 (12%) with and 2,158 (88%)
ithout DM, were randomly allocated to either invasive or
oninvasive management. Of the 299 diabetic patients, 155
ere assigned to the invasive and 144 to the noninvasive
ranch. The corresponding figures for the nondiabetic
ubjects were 1,067 (invasive) and 1,091 (noninvasive),
espectively. Pertinent baseline characteristics of the diabetic
nd nondiabetic patients are given in Table 1. The diabetic
roup was at higher risk with a higher prevalence of angina
ectoris, previous MIs, heart failure, and peripheral vascular
isease, and they were more frequently on treatment for
ypertension. The occurrence of ST-depressions or eleva-
ion of troponin-T was similar in diabetic and nondiabetic
atients. Diabetic patients were less often smokers. Admis-
ion blood glucose was significantly higher among the
iabetic patients, 9.2 3.4 mmol/l versus 5.4 1.3 mmol/l
p  0.0001).
Treatment instituted during hospitalization, as revealed
y ongoing therapy at hospital discharge, differed between
he two groups. As presented in Table 2, the diabetic
atients were more frequently given calcium-channel block-
rs, angiotensin-converting enzyme inhibitors, and diuret-
cs. As many as 41% of the diabetic patients were given
nsulin, whereas 49% were given oral agents.
ngiographic findings in the invasive group. Coronary
ngiography was available for 1,049 of the nondiabetic and
or 151 of the diabetic patients, respectively. Figure 1 clearly
emonstrates the significantly more widespread CAD
mong the diabetic cohort, with as many as 42% of these
atients categorized either as having significant three-vessel
r left main CAD compared with 31% of the nondiabetic
atients (p  0.006). The average “atheroma score” in
ondiabetic patients was 0.18, compared with 0.24 in those
ith DM (p  0.001). The proportion of nondiabetic
able 1. Baseline Characteristics of Patients With and Without
iabetes Mellitus
Parameter
Patients
p Value
No Diabetes
n  2,158
Diabetes
n  299
ge (yrs; mean  SD) 64  9 66  8 NS
en 69% (1,492) 72% (216) NS
revious
Angina pectoris 34% (733) 46% (137) 0.001
Myocardial infarction 21% (457) 30% (89) 0.001
Heart failure 2.6% (56) 6.0% (18) 0.001
Stroke 4.4% (94) 6.0% (18) NS
Peripheral vascular disease 2.9% (62) 7.7% (23) 0.001
Hypertension 28% (596) 49% (147) 0.001
PCI 3.2% (70) 3.3% (10) NS
CABG 0.4% (8) 0.3% (1) NS
moker 32% (687) 19% (58) 0.001
T depression 46% (969) 50% (145) NS
roponin T 0.03 g/l 68% (1,389) 70% (200) NS
lood glucose (mmol/l  SD) 5.4  1.3 9.2  3.4 0.001
alues are percentages and numbers are within ( ).
CABG coronary artery bypass graft; PCI percutaneous coronary intervention.
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Diabetes: Major Risk in Unstable Angina February 18, 2004:585–91atients that underwent coronary angiography without any
ubsequent coronary intervention was 21.1%, whereas
3.8% were treated with PCI and 35.2% were treated with
ABG, respectively. The corresponding proportions for the
iabetic cohort were 15.9%, 40.4%, and 43.7%, respectively.
he proportion of patients given abciximab was 10% in the
ondiabetic group and 7% among those with diabetes. The
orresponding proportion of stent use was 27% and 31% of
hose treated with PCI.
ortality and morbidity. The crude event rate as regards
I and mortality is presented in Figure 2. The diabetic
atients had a higher mortality and more myocardial rein-
arction than nondiabetic patients in both the invasive and
he noninvasive groups. Allocation to invasive management
educed the occurrence of the primary end point among
ondiabetic patients from 12% (n  131) to 8.9% (n  95)
invasive vs. noninvasive management, odds ratio [OR] 
.72; confidence interval [CI] 0.54 to 0.95; p 0.019). The
orresponding event rates in the diabetic group were signif-
cantly higher, but with a larger relative as well as absolute
eduction by the invasive strategy, 29.9% (n  43) and
0.6% (n  32), respectively (invasive vs. noninvasive
anagement OR  0.61; CI 0.36 to 1.04: p  0.066). In
igure 2, there was a similar pattern concerning mortality.
ortality was reduced from 2.7% (n 30) to 1.4% (n 15)
mong nondiabetic patient and from 12.5% (n  18) to
.7% (n  12) among diabetic patients. The probability of
eath or MI over time is shown in Figure 3, once more
emonstrating that diabetic patients, both in the noninva-
ive and invasive groups, had a significantly higher event
ate than nondiabetic patients. The proportionate improve-
ent in outcome by the invasive strategy was, however,
imilar in the two groups, and there was no interaction
etween the diagnosis of DM and management strategy.
ultivariate analysis. Because diabetic patients are a pop-
lation at higher risk than nondiabetic patients, multivariate
tatistics were applied to study whether diabetes as such was
n independent risk predictor. In this model all parameters
hat differed significantly (p  0.05) between the diabetic
able 2. Treatment at Hospital Discharge in Patients With and
ithout Diabetes Mellitus
Treatment at
Discharge
Patients
p
Value
No Diabetes
n  2,158
Diabetes
n  299
spirin 95% (2007) 95% (265) NS
eta-blockers 85% (1783) 84% (234) NS
alcium blockers 18% (390) 24% (66) 0.045
CE-inhibitors 16% (326) 36% (101) 0.001
iuretics 17% (359) 27% (76) 0.001
igitalis 3.6% (75) 5.7% (16) NS
tatins 45% (937) 40% (113) NS
nsulin 0.1% (2) 41% (115) 0.001
ral antidiabetic drug 0.6% (13) 49% (137) 0.001
alues are percentages and numbers are within ( ).
ACE  angiotensin-converting enzyme.nd the nondiabetic patient cohort as regards case history, maseline characteristics, and in-hospital management were
aken into account. Independent predictors for death or MI
n the combined invasive and noninvasive strategy groups
re depicted in Figure 4, demonstrating that DM in fact
epresents an independent predictor of risk (risk ratio [RR]
.61; CI 1.88 to 3.60; p  0.0001). Looking at mortality
nly, the corresponding independent risk increase was 5.42;
I 3.12 to 9.39; p  0.0001).
In order to study the effect of coronary artery involve-
ent, a multivariate analysis also including the extent of
AD was performed among patients in the invasive group.
hen this analysis was based on categorization according to
ne-, two-, or three-vessel disease (Fig. 5) DM remained as
n independent predictor of the combined end point (RR
.40; CI 1.47 to 3.91; p  0.0001) as well as for mortality
RR 5.43; CI 2.09 to 14.12; p  0.001). In contrast, the
raditional predictors of outcome in unstable CAD—ST-
epression, presence of three-vessel disease and age—did
ot remain as significant risk predictors for death or MI in
he invasively managed group underlining the importance of
M for the outcome. Expressing the severity of CAD
ccording to the “atheroma score” resulted in an almost
dentical risk pattern for the combined end point (RR 2.40;
I 1.47 to 3.91; p  0.001) as well as for mortality (RR
.84; CI 2.27 to 15.05; p  0.001). Although both the
umber of involved coronary arteries and the “atheroma
core” were significantly related to the combined end point
n univariable analysis (p  0.016 and p  0.022, respec-
ively), they did not remain as significant independent
rognostic variables (p  0.62 and p  0.59) after adjust-
ent for all other variables, including diabetes, in the
ultivariate analysis in the invasive group.
igure 1. Number of coronary arteries with significant lesions in patients
ith (hatched bars) and without (open bars) diabetes mellitus. Figures
ithin brackets represent number of patients in each group. LM  left
ain coronary artery.
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February 18, 2004:585–91 Diabetes: Major Risk in Unstable AnginaISCUSSION
he main finding in this subgroup analysis of the FRISC II
rial, investigating management strategies in unstable CAD,
s that patients with DM had a significantly higher rate of
eath or MI than did nondiabetic patients. This was
pparent both in invasively and noninvasively managed
atients. The outcome for diabetic patients was considerably
orse even with the invasive strategy than for noninvasively
andled patients without diabetes (event rates 21% and
2%, respectively). Notably, the relative impact of an early
nvasive strategy was of the same magnitude in both diabetic
nd nondiabetic patients. This means that the absolute
ffect in people with diabetes was substantially larger than in
he nondiabetic group: approximately 11 patients with
iabetes had to be treated for one saved MI or death with an
nvasive strategy, compared with 32 nondiabetic patients.
A limitation with the present investigation, as with most
tudies on treatment effects in patients with diabetes, is that
t originates from a retrospective subgroup analysis. Even if
he number of patients with diabetes were enough for
omparing their outcomes to those without diabetes, from
n epidemiologic perspective it may be argued that the
roportion of diabetic patients, 12%, is rather low. From
revious studies we know that in populations with acute MI
nd with unstable angina at least about 20% have DM
15–18). Thus, there may be a selection bias in FRISC II,
ith the implication that some diabetic patients may have
een excluded despite fulfilling the inclusion criteria. At the
ime of patient recruitment, there may have been a hesitancy
o expose diabetic patients with acute coronary syndromes
o early coronary interventions. This assumption gets sup-
ort from a recent survey based upon the Register of
nformation and Knowledge about Swedish Heart Intensive
are (RIKS-HIA) (17) demonstrating that patients with
M and acute MI are significantly less often revascularized
ithin 14 days from hospital discharge. Thus, it may very
ell be that the most complex diabetic patients were in fact
xcluded. In that case the present results will, if anything,
igure 2. Crude one-year event rates as regards myocardial infarction (M
nvasive (hatched bars) and noninvasive (open bars) management strategnderestimate the true risk of the combination of DM and Ocute coronary syndromes. It is obvious that the present data
onfirm previous reports on the dismal prognosis for dia-
etic patients with acute coronary syndromes (2,16,17). It
ruly underlines that non–Q-wave MIs and unstable angina
re major events among people with DM.
The data from the Swedish RIKS-HIA demonstrate that
atients with DM and acute MI are less often offered
stablished, evidence-based pharmacologic treatment and
re significantly less often revascularized during the imme-
iate postinfarction period (17). The present data provide
o reason for such an underutilization. Instead, the results
upport an increased awareness for an early invasive ap-
roach in patients with diabetes. However, it should be
mphasized that despite the best available treatment strat-
gy, diabetic patients were left with a substantially higher
ortality and morbidity than their nondiabetic counter-
arts. Accordingly, there must also be other factors to take
nto account when discussing the optimal treatment of
iabetic patients.
As expected and previously shown (10,11), diabetic pa-
ients had more extensive CAD. However, diabetes was an
ndependent predictor of the primary composite end point
mortality in patients with and without diabetes mellitus subjected to an
text for further explanation). OR  odds ratio.
igure 3. The probability of death or myocardial infarction over time.I) and
y (seeR  odds ratio.
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Diabetes: Major Risk in Unstable Angina February 18, 2004:585–91nd for mortality even after statistical adjustment for all
aseline dissimilarities including the extent of CAD evalu-
ted in two different ways, signs of myocardial damage and
or revascularization. In contrast to most other risk indica-
ors, DM remained a strong predictor of a worse outcome
ven after elimination of the most important flow-limiting
oronary lesion. The most reasonable explanation for these
ndings is that the diabetic state by itself is important for
he final outcome. This highlights the impact of diabetes
ven in a revascularized group and offers support for further
iabetes-specific therapy with the intention to improve
utcome in these high-risk patients.
Several mechanisms may contribute to the increased risk
n type 2 diabetic patients, as recently reviewed (19).
otably, thromboembolic events are promoted by a combi-
ation of increased platelet aggreggability and decreased
brinolytic function. Endothelial dysfunction deteriorates
yocardial flow reserve, and the myocardial diastolic func-
ion is often compromised in the diabetic heart, which,
specially in stressful situations, is forced to an unfavorable
etabolism characterized by an increased rate of beta-
xidation of free fatty acids. Many, if not all, of these
erturbations may be counteracted by intense insulin-based
etabolic control (20,21). It has also been noted that
ffective antithrombotic treatment may be of a particular
alue in the diabetic patient (22).
The present study did not define whether an early
ntervention should be a PCI or a bypass procedure
CABG). This decision was at the discretion of the physi-
ian in charge and no randomization was undertaken
etween the different procedures. It is therefore not possi-
le, on the basis of FRISC II data, to elaborate on the
reference of technique for the diabetic compared with the
ondiabetic patient. Still, the choice of revascularization
rocedure, PCI or CABG, may be of great importance for
he final outcome. The BARI trial clearly indicates that
iabetic patients with multivessel disease benefit from
igure 4. Independent predictors for the composite primary end point
death or myocardial infarction [MI]) in the total patient cohort (invasive
nd noninvasive strategy patients) according to multivariate statistics. The
cale on the x-axis is logarithmic. CI  confidence interval; RR  risk
atio.ABG compared to PCI (15). The major problem withCI in diabetic patients is the high rate of restenosis that
robably translates into a decreased survival (15,23,24). The
resent result was obtained with limited use of stent
mplantations and GP IIb/IIIa infusions. It may be antici-
ated that modern PCI, including a more liberal use of stent
mplantation and GP IIb/IIIa prescription, drug-eluting
tents, and new platelet-stabilizing drugs, may reduce the
ate of restenosis (22,25,26), offering diabetic patients more
pportunities to successful PCI.
In summary, the present data give strong support to the
pdated version of the European Guidelines (27) stating
hat diabetic patients with non–ST-elevation acute coronary
yndromes should be defined as patients at high risk for
ortality and new infarcts. This risk is not only linked to
onventional factors such as the extent of the CAD or size
f myocardial damage, but seems also to a large extent
elated to factors specific to the metabolic disease. Early
evascularization seems to have the same relative beneficial
ffect in both diabetic and nondiabetic patients. Hence, an
arly intervention strategy might be an important part of the
reatment of diabetic patients with acute coronary syn-
romes. This should, however, be supplemented with fur-
her therapies and strategies directed towards the many
bnormalities that are associated with DM, such as endo-
helial dysfunction, dysglycemia, and coagulation and fi-
rinolytic disturbances. Key targets for additional treatment
eed to be evaluated in forthcoming trials in diabetic
atients with and without revascularization.
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